Ask AI
ProCE Banner Activity

Second-line Agents for Achieving Treatment Goals: Raising the Bar in PBC Management Podcast

Podcast Episodes

New therapeutic agents for second-line treatment are raising the bar for primary biliary cholangitis (PBC) management. Listen now as Dr Aliya F. Gulamhusein, Dr Christopher L. Bowlus, and Dr Aparna Goel, discuss how to incorporate these new agents into clinical practice and how these agents will impact attainment of treatment goals.

This episode is the second of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care.

Released: December 11, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This activity is intended for physicians, including hepatologists and gastroenterologists, physician associates, nurse practitioners, and other HCPs involved in the care of patients with PBC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop treatment goals for PBC that include evidence-based biochemical targets and improvement in symptoms and quality of life

  • Outline the role of new PBC therapies in achieving biochemical targets and symptom management

  • Design comprehensive treatment plans for patients with PBC

Disclosure

Primary Author

Christopher L. Bowlus, MD: researcher (paid to institution): Calliditas, ChemoMab, COUR, Cymabay, Gilead, GSK, Hanmi, Ipsen, Mirum, Novartis, Pliant, Zydus; consultant/advisor/speaker: Alnylam, Amgen, AstraZeneca, ChemoMab, Esperion, Gilead, GSK, Ipsen, Kezar, Mirum, Pliant, Takeda.

Aparna Goel, MD: consultant/advisor/speaker/researcher: Gilead, Ipsen, Mirum.

Aliya F. Gulamhusein, MD, MPH, FRCPC: consultant/advisor/speaker: Advanz, Gilead, Ipsen, Mirum.